Trajan Group Holdings Limited (ASX:TRJ)
Australia · Delayed Price · Currency is AUD | Market Cap | 57.22M -56.3% |
| Revenue (ttm) | 169.52M +6.2% |
| Net Income | -1.38M |
| EPS | -0.01 |
| Shares Out | 152.59M |
| PE Ratio | n/a |
| Forward PE | 10.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 85,723 |
| Average Volume | 34,862 |
| Open | 0.3800 |
| Previous Close | 0.3750 |
| Day's Range | 0.3550 - 0.3900 |
| 52-Week Range | 0.3550 - 0.9700 |
| Beta | 0.57 |
| RSI | 34.84 |
| Earnings Date | May 27, 2026 |
About Trajan Group Holdings
Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India. The company offers analytical products, including syringes, GC columns and septa, inlet liners, rings, and tubing products; and sampling products, comprising septa, caps, liners, well plates and sealing mats, crimping tools, and micro sampling tools, as well as automation systems and consumables. It also provides pathology produ... [Read more]
Financial Performance
In fiscal year 2025, Trajan Group Holdings's revenue was 166.46 million, an increase of 7.38% compared to the previous year's 155.02 million. Losses were -4.46 million, -82.39% less than in 2024.
Financial StatementsNews
Trajan Group Holdings Earnings Call Transcript: H1 2026
H1 FY26 revenue grew 3.8% to AUD 84.1 million, with strong Q2 momentum supporting full-year guidance for record revenue and EBITDA. Strategic investments and Project Neptune cost savings are expected to drive H2 margin improvement, despite ongoing macroeconomic and currency risks.
Trajan Group Holdings Transcript: AGM 2025
The meeting highlighted strong revenue growth, improved balance sheet, and ongoing margin challenges. Strategic initiatives included extending key customer relationships, new product launches, and operational improvements. All resolutions were put to vote with no questions raised.
Trajan Group Holdings Earnings Call Transcript: H2 2025
Record FY 2025 revenue of $166.5M (+7.4%) and EBITDA up 26%, with strong growth in consumables and disruptive tech. Margin pressure in capital equipment offset by operational efficiencies and a shift to in-region supply. Conservative FY 2026 outlook amid tariff and funding volatility.
Trajan Group Holdings Earnings Call Transcript: H1 2025
H1 FY2025 saw 6% revenue growth, strong EBITDA gains, and margin improvements, with robust order books and ongoing margin initiatives. Guidance is confirmed despite U.S. and pharma sector headwinds, and net debt is below target. Defensive end markets and global diversification support resilience.
Trajan Group Holdings Transcript: AGM 2024
The meeting reviewed a year of resilience, with a strong second-half rebound and reaffirmed financial guidance. Key resolutions were voted on, strategic acquisitions highlighted, and industry trends discussed, including global supply chain shifts and sector resilience.
Trajan Group Holdings Earnings Call Transcript: H2 2024
FY 2024 revenue was AUD 155 million, with EBITDA above guidance and net debt reduced by AUD 4.7 million. Despite destocking headwinds, order recovery and margin improvements position the business for FY 2025 growth, with revenue expected to exceed AUD 160 million.